BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27521326)

  • 1. Trends in Clinical Investigation for Myelodysplastic Syndromes.
    Prebet T; Zeidan A
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S57-63. PubMed ID: 27521326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.
    Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S39-43. PubMed ID: 27521322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?
    Bewersdorf JP; Zeidan AM
    Expert Rev Hematol; 2020 Oct; 13(10):1131-1142. PubMed ID: 32876498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy-related myelodysplastic syndromes, or are they?
    Abou Zahr A; Kavi AM; Mukherjee S; Zeidan AM
    Blood Rev; 2017 May; 31(3):119-128. PubMed ID: 27923516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.
    Kewan T; Stahl M; Bewersdorf JP; Zeidan AM
    Curr Hematol Malig Rep; 2024 Jun; 19(3):138-150. PubMed ID: 38632155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of patients with higher risk myelodysplastic syndromes.
    Fukumoto JS; Greenberg PL
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):179-92. PubMed ID: 15979321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Established and emerging targeted therapies in the myelodysplastic syndromes.
    Canaani J; Nagler A
    Expert Rev Hematol; 2016 Oct; 9(10):997-1005. PubMed ID: 27615383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.
    Burgstaller S; Wiesinger P; Stauder R
    Drugs Aging; 2015 Nov; 32(11):891-905. PubMed ID: 26476843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent advances in the treatment of myelodysplastic syndromes].
    Gelsi-Boyer V; Vey N
    Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
    Wang C; Sallman DA
    Curr Treat Options Oncol; 2023 May; 24(5):387-408. PubMed ID: 36966266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations.
    Nazha A; Sekeres MA
    Annu Rev Med; 2017 Jan; 68():127-137. PubMed ID: 27618752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current therapy of myelodysplastic syndromes.
    Zeidan AM; Linhares Y; Gore SD
    Blood Rev; 2013 Sep; 27(5):243-59. PubMed ID: 23954262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes.
    Scott BL; Deeg HJ
    Annu Rev Med; 2010; 61():345-58. PubMed ID: 20059342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The wider perspective: twenty years of clinical trials in myelodysplastic syndromes.
    Duetz C; Cucchi DGJ; Polak TB; Janssen JJWM; Ossenkoppele GJ; Estey EH; van de Loosdrecht AA
    Br J Haematol; 2022 Jan; 196(2):329-335. PubMed ID: 34632583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current management of myelodysplastic syndromes].
    Vey N; Charbonnier A
    Rev Prat; 2010 Dec; 60(10):1416-9. PubMed ID: 21425543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.
    Roberts DA; Steensma DP
    Curr Hematol Malig Rep; 2015 Sep; 10(3):318-28. PubMed ID: 26126600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.